Sector portfolio · VC firm · United States
Cormorant Capital's Biotech portfolio
Cormorant Capital has backed 20 Biotech startups in rounds we track, $4.6B between them, shown by the stage each has reached. The best-funded is Bridgebio.
Funding by segment
- Series C and later$2.0B11
- Series B$1.0B6
- Stage not reported$1.6B3
Where they are based
- United States15$3.7B
- United Kingdom3$542M
- China2$344M
United States
United Kingdom
ChinaFounded
8 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M0
- $10M to $50M2
- $50M to $250M11
- $250M to $1B6
- $1B and over1
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
12 of 20 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States15
- United Kingdom3
- China2
Startups by country, 3 countries in all.
Segment by segment
Series C and later
11 startups · $2.0B raised
Orchard TherapeuticsOrchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.United Kingdom$377M
Solid BiosciencesSolid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.United States$333M- AAtrecaAtreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.United States$313M
- ZLZai LabChina$310M
908 Devices908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.United States$168M- TTTP TherapeuticsUnited States$126M
FORE BiotherapeuticsFore Biotherapeutics is a clinical-stage precision oncology company based in Philadelphia, PA.United States$108M- AAutolousUnited Kingdom$80M
Series B
6 startups · $1.0B raised
Akero TherapeuticsAkero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.United States$502M
Stoke TherapeuticsStoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.United States$255M- RReplimuneUnited Kingdom$85M
- EEdiosUnited States$64M
- CCorvidiaCorvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.United States$61M
- CCMABChina$34M
Stage not reported
3 startups · $1.6B raised
BridgeBioBridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.United States$1.4B- PPrecisionUnited States$111M
- SPSasuma PharmaceuticalsUnited States$62M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Cormorant Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like Cormorant Capital?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.